Risk of Thromboembolic Events in Controlled Trials of rFVIIa in Spontaneous Intracerebral Hemorrhage | Zendy

Michael N. Diringer | Zendy; Brett E. Skolnick | Zendy; Stephan A. Mayer | Zendy; Thorsten Steiner | Zendy; Stephen M. Davis | Zendy; Nikolai C. Brun | Zendy; Joseph P. Broderick | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Risk of Thromboembolic Events in Controlled Trials of rFVIIa in Spontaneous Intracerebral Hemorrhage

Author(s) -

Michael N. Diringer,

Brett E. Skolnick,

Stephan A. Mayer,

Thorsten Steiner,

Stephen M. Davis,

Nikolai C. Brun,

Joseph P. Broderick

Publication year - 2008

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.107.493601

Subject(s) - medicine , intracerebral hemorrhage , placebo , stroke (engine) , anesthesia , hematoma , adverse effect , odds ratio , recombinant factor viia , randomized controlled trial , surgery , cardiology , subarachnoid hemorrhage , mechanical engineering , alternative medicine , pathology , engineering

Recombinant activated factor VII (rFVIIa) reduces hematoma expansion and improves outcome after intracerebral hemorrhage (ICH), with an apparent increase in nonfatal thromboembolic events (TEs) with higher doses. Despite low incidences of such events in rFVIIa-treated hemophiliacs, the frequency in older patients with more atherosclerosis and immobility has yet to be defined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research